Supernus Pharmaceuticals Inc (SUPN) was Downgraded by Northland Capital to ” Market Perform”. Earlier the firm had a rating of “Outperform ” on the company shares. Northland Capital advised their investors in a research report released on Jul 18, 2016.
Many Wall Street Analysts have commented on Supernus Pharmaceuticals Inc. Supernus Pharmaceuticals Inc was Downgraded by Piper Jaffray to ” Neutral” on Jul 18, 2016.
On the company’s financial health, Supernus Pharmaceuticals Inc reported $0.08 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.09. The company had revenue of $43.00 million for the quarter, compared to analysts expectations of $45.32 million. The company’s revenue was up 53.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.02 EPS.
Supernus Pharmaceuticals Inc closed down -0.01 points or -0.05% at $21.84 with 3,28,791 shares getting traded on Friday. Post opening the session at $22.02, the shares hit an intraday low of $21 and an intraday high of $22.13 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Jul 15, 2016, Gregory S Patrick (VP, Chief Financial Officer) sold 3,395 shares at $22.00 per share price. According to the SEC, on Apr 12, 2016, Padmanabh P. Bhatt (Sr. VP of IP, CSO) sold 30,762 shares at $16.49 per share price. On Dec 8, 2015, M James Barrett (director) sold 212,970 shares at $14.56 per share price, according to the Form-4 filing with the securities and exchange commission.
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD) autism and bipolar disorder) and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR Trokendi XR SPN-810 SPN-812 and SPN-809.